Making it in Manufacturing podcast

The CEO’s Weekly Challenge: Capacity or Indication | CPHI Milan 2026 CEO Panel

0:00
42:27
Reculer de 15 secondes
Avancer de 15 secondes

This week on Making It In Manufacturing, we’re bringing you our CEO panel from CPHI Milan 2026. ARTO Co-Founder and CEO Elliot Payne sat down with three CDMO CEOs: Dr Hanns-Christian Mahler of ten23 health, Dr Adriana Kiędzierska-Mencfeld of Rezon Bio and Philippe Clavel of Curapath, to ask how they weigh capacity risk against indication risk.


In this panel:

- Why ordering a sterile filling machine today can mean five to seven years before the first GMP fill

- How Rezon Bio builds capacity in stages, and why the team is the biggest asset and the biggest risk

- How Curapath helped an ALS customer go from 16 polymer drug conjugates to four on the way to phase two

- Fixed platforms with flexible indications, and when one facility can serve many

- The latest build, buy or partner calls each CEO has made

- Data or instinct: how they decide where to invest next

- The one thing each of them would remove from pharma manufacturing


Be sure to watch to the end for the quickfire round.


Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto


🤝 Thank you to CPHI and Informa Markets for having us as official podcast partners at CPHI Milan 2026.


Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent

TikTok: https://www.tiktok.com/@artotalent

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

YouTube: https://www.youtube.com/@artotalent

Making It In Manufacturing playlist: https://www.youtube.com/playlist?list=PL_xXnfiK8dI5gHJr13c23WSFNHYc4d6_4


The panel :

Hanns-Christian Mahler, CEO, ten23 health: https://www.linkedin.com/in/hanns-christian-mahler/

Adriana Kiędzierska-Mencfeld, CEO, Rezon Bio: https://www.linkedin.com/in/dr-adriana-kiedzierska-mencfeld/

Philippe Clavel, CEO, Curapath: https://www.linkedin.com/in/philippe-clavel-cdmo-gxapis/

Moderated by Elliot Payne, Co-Founder and CEO, ARTO: https://www.linkedin.com/in/elliot-payne-2a4a917a/


Timestamps:

0:00 Intro

0:15 Welcome to the CEO’s Weekly Challenge

0:50 How do you weigh capacity risk against indication risk?

6:50 ten23 health: the science, not the disease

9:06 Do biosimilars take indication risk out?

10:56 Curapath’s ALS customer: from 16 conjugates to four

12:28 Fixed platform, flexible indications

15:31 Fast, flexible capacity: real or a marketing ploy?

23:29 Biosimilars: flexibility or analytical rigour?

26:03 Can one facility serve many indications and be best in class?

28:29 The latest build, buy or partner call

33:35 Data or instinct?

40:34 Quickfire: one thing to remove from pharma manufacturing


#MakingItInManufacturing #ARTOTalent #CPHIMilan #CPHI2026 #CDMO #PharmaManufacturing #Biotech #LifeSciences #Biosimilars #DrugDelivery

Hosted on Acast. See acast.com/privacy for more information.

D'autres épisodes de "Making it in Manufacturing"